Mechelen, Belgium; 31 October 2018; 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing
in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF).
PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial investigating a 100 mg once-daily oral
dose of GLPG1205 in up to 60 IPF patients. The first patient was dosed in a center opened in Slovakia.
Galapagos currently has three drug candidates with distinct mechanisms of action in its fully proprietary
portfolio aimed at building an IPF franchise: GLPG1690 in the ISABELA Phase 3 program, GLPG1205 in the PINTA Phase 2 trial, and
GLPG3499, currently in pre-clinical development.
"The first patient dosing in our PINTA Phase 2 trial shows the progress we are making in expanding our IPF
franchise," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos. "We are strongly committed to the rapid development of
our fully proprietary IPF portfolio to address this important unmet medical need."
About GLPG1205
GLPG1205, fully proprietary to Galapagos, is a small molecule selectively antagonizing GPR84. Galapagos identified the GPR84 target
using its proprietary target discovery platform and developed GLPG1205 as an antagonist of this target. GLPG1205 showed promising
results in relevant pre-clinical models for IPF, and there is growing evidence in scientific literature and in clinical research
that GPR84 plays a role in this disease. GLPG1205 successfully completed several Phase 1 trials, showing favorable findings
relating to tolerability, and target engagement in healthy volunteers. GLPG1205 showed good tolerability but no activity in
ulcerative colitis patients in 2016. GLPG1205 is an investigational drug and its efficacy and safety have not yet been
established.
For information about the studies with GLPG1205: www.clinicaltrials.gov (NCT03725852)
For more information about GLPG1205: www.glpg.com/ipf
About IPF
IPF is a chronic, relentlessly progressive fibrotic disorder of the lungs that typically affects adults over the age of 40. There
are approximately 200,000 patients with IPF in the U.S. and Europe. As such, IPF is considered a rare disease. The clinical
prognosis of patients with IPF is poor as the median survival at diagnosis is 2 to 4 years. Currently, no medical therapies have
been found to cure IPF. The medical treatment strategy aims to slow the disease progression and improve the quality of life.
About the PINTA trial
PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial investigating a 100 mg once-daily oral dose of GLPG1205. The
drug candidate or placebo will be administered for 26 weeks in up to 60 IPF patients. Patients may remain on their local standard
of care as background therapy, whether or not they were previously or currently are treated with Esbriet®[1]
(pirfenidone) and Ofev®[2] (nintedanib). The primary objective of the trial is to assess the change from
baseline in Forced Vital Capacity (FVC in mL) over 26 weeks compared to placebo. Secondary measures include safety, tolerability,
pharmacokinetics and pharmacodynamics, time to major events, changes in functional exercise capacity, and quality of life.
Recruitment for PINTA is planned in 10 countries in Europe, North Africa, and the Middle East.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small
molecule medicines with novel modes of action. Galapagos' pipeline comprises Phase 3 through to discovery programs in inflammation,
fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing
promising patient results in, respectively, inflammatory diseases, idiopathic pulmonary fibrosis and atopic dermatitis. Galapagos
is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 700 employees, operating from its Mechelen, Belgium headquarters
and facilities in the Netherlands, France, Switzerland, the US and Croatia. More information at www.glpg.com.
Contact
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Sofie Van Gijsel
Director IR
+32 485191415
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking statements, including statements regarding Galapagos' strategic ambitions, the mode of
action and/or potential activity of GLPG1205, the anticipated timing of future clinical studies with GLPG1205, the progression and
results of such studies and the unmet medical need for IPF treatments. Galapagos cautions the reader that forward-looking
statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance
or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance,
financial condition and liquidity, and the development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may
result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product
development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research
programs may not support registration or further development of GLPG1205 due to safety, efficacy or other reasons), and estimating
the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other
risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most
recent annual report on Form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given
these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation
to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking statements, unless specifically required by law or
regulation.
[1] Esbriet® (pirfenidone) is an approved drug for IPF, marketed by Roche/Genentech
[2] Ofev® (nintedanib) is an approved drug for IPF, marketed by Boehringer Ingelheim
